基本信息
浏览量:1413
职业迁徙
个人简介
Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection.
In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.
In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.
In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.
In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.
研究兴趣
论文共 673 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Tae Kon Kim,Xue Han,Qianni Hu, Esten N. Vandsemb, Carly M. Fielder,Junshik Hong,Kwang Woon Kim,Emily F. Mason, R. Skipper Plowman,Jun Wang,Qi Wang, Jian-Ping Zhang,
JOURNAL OF CLINICAL INVESTIGATIONno. 3 (2024)
ANNALS OF SURGICAL ONCOLOGYno. 1 (2024): 25-27
Matthew D. Vesely, Michal Kidacki,Patricia Gaule, Swati Gupta,Nay Nwe Nyein Chan,Xue Han,Jacky T. Yeung,Lieping Chen
Tae Kon Kim,Xue Han,Qianni Hu, Esten N Vandsemb, Carly M Fielder,Junshik Hong,Kwang Woon Kim,Emily F Mason, R Skipper Plowman,Jun Wang,Qi Wang,Jian-Ping Zhang,
The Journal of clinical investigationno. 3 (2024)
Magali Terme,Evelyn Ullrich,Laetitia Aymeric, Kathrin Meinhardt,Jérôme D. Coudert,Mélanie Desbois,François Ghiringhelli,Sophie Viaud,Bernard Ryffel,Hideo Yagita,Lieping Chen, Salaheddine Mécheri,
crossref(2023)
Chunhua Wang,Quan Chen, Meiqing Chen, Sizhen Guo,Ping Hou,Yulian Zou,Jun Wang,Bailin He,Qiuyu Zhang,Lieping Chen,Liqun Luo
CANCER IMMUNOLOGY IMMUNOTHERAPYno. 6 (2023): 1685-1698
Magali Terme,Evelyn Ullrich,Laetitia Aymeric, Kathrin Meinhardt,Jérôme D. Coudert,Mélanie Desbois,François Ghiringhelli,Sophie Viaud,Bernard Ryffel,Hideo Yagita,Lieping Chen, Salaheddine Mécheri,
crossref(2023)
Fumiya Hirano, Katsumi Kaneko,Hideto Tamura,Haidong Dong,Shengdian Wang,Masao Ichikawa, Cecilia Rietz,Dallas B. Flies, Julie S. Lau,Gefeng Zhu,Koji Tamada,Lieping Chen
crossref(2023)
Yuanzhen Peng,Solomon Langermann, Priyanka Kothari,Linda Liu,Wei Zhao,Yizhong Hu, Zihao Chen,Mariana Moraes de Lima Perini,Jiliang Li,Jay Cao,X. Edward Guo,Lieping Chen,
JBMR PLUSno. 12 (2023): n/a-n/a
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn